Skip to main content

Kathleen M. Neuzil, MD, MPH, FIDSA

Myron M. Levine, MD, DTPH Professor of Vaccinology

Academic Title:


Primary Appointment:


Secondary Appointment(s):


Administrative Title:

Division Head, Geographic Medicine; Director for the Center for Vaccine Development and Global Health

Additional Title:

Myron M. Levine, MD, DTPH Professor in Vaccinology and Director, Center for Vaccine Development and Global Health


HSF I 480G

Phone (Primary):




Education and Training

  • University of Maryland (summa cum laude), B.S., Zoology, 1983
  • Johns Hopkins University School of Medicine (Alpha Omega Alpha (AOA) Honor Medical Society), 1987
  • Residency, Vanderbilt University School of Medicine, Internal Medicine, 1987-1991
  • Fellowship, Vanderbilt University School of Medicine, Infectious Diseases, 1991-1994
  • Vanderbilt University School of Medicine, M.P.H., 1998


Kathleen Neuzil is the Myron M. Levine Professor in Vaccinology, Professor of Medicine and Pediatrics, and the Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. She is an internationally recognized research scientist and advocate in the field of vaccinology.

Throughout her career, Dr. Neuzil has conducted clinical and epidemiologic studies on vaccine-preventable diseases. Dr. Neuzil’s work has spanned dozens of countries with multiple vaccines, including influenza, rotavirus, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, and most recently, COVID-19 vaccines. She has more than 330 scientific publications on vaccines and infectious diseases.

Dr. Neuzil's research capabilities are complemented by 20 years of involvement in domestic and international vaccine policy, including past membership on the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. She is a member of the World Health Organization Strategic Advisory Group of Experts on Immunization and is a member of the National Academy of Medicine.



Research/Clinical Keywords

Global public health, infectious diseases, vaccine access and delivery, vaccine safety, rotavirus, pandemic influenza, immunization, maternal immunization, diarrheal diseases, maternal child health, reproductive health, sexually transmitted diseases, COVID-19, vaccinology, human papillomavirus, Japanese encephalitis, typhoid conjugate vaccines, TyVAC

Highlighted Publications

  1. Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, Neuzil KM, Gordon MA; TyVAC team. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet. 2024 Feb 3;403(10425):459-468. doi: 10.1016/S0140-6736(23)02031-7. Epub 2024 Jan 25. PMID: 38281499; PMCID: PMC10850983.
  2. Ortiz JR, Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, Brady RC, Bryant C, Wegel A, Frenck RW, Walter EB, Abate G, Williams SR, Atmar RL, Keitel WA, Rouphael N, Memoli MJ, Makhene MK, Roberts PC, Neuzil KM. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 Aug 11;228(3):287-298. doi: 10.1093/infdis/jiad021. PMID: 36702771; PMCID: PMC10420403.
  3. Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, Suthar MS, Coler RN, Berube BJ, Kim SH, Piper JM, Miller AM, Cardemil CV, Neuzil KM, Beigi RH; DMID 21-0004 Study Group. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.06.032. Epub ahead of print. PMID: 37451878; PMCID: PMC10261713.
  4. Neuzil KM, Anderson EJ, Frenck RW, Frey SE, Walter EB, Rupp R, Rotrosen ET, Rouphael NG, Brady RC, Graham I, Schmader KE, Porterfield L, Ortiz JR, Swamy GK, El Sahly HM, Jeevan T, Sitaula R, Wegel A, Webby RJ, Bryant C; Influenza A/H5N8 Virus Vaccine Group. Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses. Clin Infect Dis. 2023 Jan 5:ciac982. doi: 10.1093/cid/ciac982. Epub ahead of print. PMID: 36610728.
  5. Neuzil KM. Enteric Fever - Tools for Prevention. N Engl J Med. 2023 Apr 20;388(16):1526-1528. doi: 10.1056/NEJMe2300753. PMID: 37075145.

Research Interests

Dr. Neuzil's research focuses on vaccine development and introduction in under-developed areas. She works on a variety of vaccines, including influenza, typhoid, and COVID-19, as well as on cross-cutting issues such as maternal immunization, optimizing vaccine use, and overcoming barriers to sustainable vaccine uptake in low resource settings. Dr. Neuzil is central to the domestic and global response to COVID-19.

Her capabilities range from epidemiology and clinical trials to expertise in vaccine research and development, partnerships with vaccine manufacturers, and domestic and international health policy.

Awards and Affiliations

  • The Myron M. Levine, MD Professorship in Vaccinology (Endowed Professorship), University of Maryland School of Medicine, 2019
  • National Academy of Medicine; Member 2019-present
  • Chair, Pandemic Influenza Task Force, Infectious Disease Society of America (IDSA) 2005-2008; Member 2008-present
  • Member, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, 2006-2010 (Chair, Influenza Vaccine Working Group, 2008-2010; Chair, Vaccines in Pregnancy Working Group 2006-2008)
  • PATH Vision Award in the Advancing Global Health Category for the Cervical Cancer Prevention Project, 2009
  • Joseph E. Smadel lectureship, IDSA Annual Meeting, Vancouver, CA, 2010
  • Member of the World Health Organization Strategic Advisory Group of Experts on Immunization
  • 2020 Baltimore Sun Marylander of the Year Awardee
  • 2020 Fierce Pharma "The 22 Most Influential People in the Fight Against COVID-19"
  • 2021 Sonia Skarlatos Public Service Award from the American Society of Gene & Cell Therapy
  • 2021 Annual Boy Scouts of Central Maryland Health Services Leadership Award for Outstanding Service
  • 2021 University of Maryland Baltimore Exemplary Service During Pandemic Award
  • 2023 University of Maryland Baltimore Researcher of the Year Award
  • VRC Scientific Advisory Panel, NIH, 2020 - Present
  • WHO Department of Immunization, Vaccine & RSV Biologicals Technical Advisory Group, 2020 - Present
  • Co-Director of COVID-19 Prevention Network, 2020 - Present
  • Member Advisory Group for the Global Typhoid Genomics Consortium, 2021 - Present
  • Senior Advisor to the Global Virus Network (GVN), 2021 - Present
  • Member BactiVac Network Adivsory Board, 2021 - Present

Grants and Contracts

03/01/19-04/30/24      (PI: 5%)                                                                              Effect of a novel typhoid conjugate vaccine in Africa:  a multicenter study in Ghana and the Democratic Republic of the Congo (THECA) (“the research”)

04/15/19-04/30/24      (Protocol PI: 3%)                                                            Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation, Natural History Challenge Study for Influenza, Task Area B-C, 18-0010.B1C1.0120." NIAID Vaccine Treatment and Evaluation Unit, FY. 2018.B1C1.0120

09/16/19-09/15/26      (Contact PI: 20%)                                                “Collaborative Influenza Vaccine Innovation Centers (CIVICs) Component C: Clinical Core.” National Institute of Allergy and Infectious Disease (NIAID), 75N93019C00055

12/05/19-11/30/26 (Co- PI, Multi-PI Award: 20%) Contact PI: David Stephens, Emory  “Leadership Group for Infectious Diseases Clinical Research Consortium (IDCRC).”  NIH, NIAID, 1UM1AI148684-01   

 12/11/19-11/30/26       (Co-Investigator: 10%)                                    “Implementing Vaccine Treatment and Evaluation Unit (VTEU) Clinical Site Protocols."  NIH, NIAID, UM1AI148689

11/01/21–10/31/25      (PI)                                                                        “Accelerating Access to Typhoid Conjugate Vaccines” (TyVAC 2.0) . Sponsor: Bill and Melinda Gates Foundation

05/01/22–03/31/24      (PI)                                                                            “Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever." Sponsor: National Institute of Allergy and Infectious Disease (NIAID), HHSN272201700082C

05/01/23–04/30/25      (PI)                                                                                          “A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of DCFHP-Alum, A Spike-Functionalized Ferritin Nanoparticle Vaccine Targeting COVID-19, Co-formulated with Aluminum Hydroxide Adjuvant, in Health Adults in the United States.” Sponsor: Vaccine Company, Inc.

06/01/23–04/30/28     (PI)                                                                       “Development of a multivalent variant-proof mucosal SARS-CoV-2 vaccine.” Sponsor: National Institute of Health (NIH).








In the News

Dr. Neuzil is regularly interviewed and quoted as a vaccine expert.

Recent news includes:

Professional Activity

Dr. Kathleen Neuzil have over 25 years of experience in infectious diseases and vaccine science, policy & leadership. Her capabilities range from proficiency in epidemiology and clinicals trials to expertise in vaccine research & development, partnerships with developing country vaccine manufacturers, & knowledge & experience with domestic & international regulatory practices. Dr. Neuzil's vaccine research on influenza, rotavirus, pertussis, and typhoid vaccines, among others, has advanced science and influenced policy. These studies have ranged from designing and executing Phase 1 trials to leading pivotal clinical trials, including large multicenter field studies and cluster-randomized trial. 

Based on Dr. Neuzil's broad influenza and vaccine experience, she was selected as co-director of the Coronavirus Prevention Network (CoVPN), a network of NIH-funded sites who participated in the US-supported Phase 3 trials of Covid-19 vaccines.  As such, she was part of the strategic team evaluating COVID vaccines and therapeutics in the US, being involved in the conception, design, execution, analysis, and interpretation of these studies. 

Dr. Neuzil's research and leadership capabilities are complimented by over two decades of involvement in domestic & international vaccine policy, including membership on CDC’s Advisory Committee on Immunization Practices (ACIP) and past & current advisory positions on World Health Organization (WHO) vaccine policy committees.  She is currently a member of the WHO Strategic Advisory Group of Experts on Immunization (SAGE).

Dr. Kathy Neuzil has a strong commitment to mentoring the next generation of vaccine scientists & leaders. This includes formal academic mentorship & participation on masters & PhD dissertation committees. She currently serves as Contact PI (Multi PI mechanism) on the Center for Vaccine Development and Global Health's NIAID T32 Training Grant in Vaccinology, and as a mentor on K01 Awards. As PI or Co-PI of large multicenter initiatives funded by NIH & the Gates Foundation, she actively seeks opportunities for trainees.